|
 Bristol Myers gained the drug, approved last year for treating
multiple sclerosis patients, in 2019 through its $74 billion buyout
of Celgene.
Zeposia last year June met the main goals of a late-stage study,
showing patients who took it achieved clinical remission of
ulcerative colitis when compared to placebo. (https://reut.rs/2SA6RFe)
Cowen analyst Steve Scala, in a note on May 23, estimated Zeposia
sales of $150 million in 2021, $400 million in 2022 and $1 billion
in 2025.
[to top of second column] |
 Zeposia will compete with
Takeda Pharmaceutical Co's drug Entyvio, which
was approved in 2014 by the FDA for ulcerative
colitis.
The European Medicines Agency is currently
reviewing the marketing application for Zeposia
to treat ulcerative colitis. A decision from the
agency is expected in the second half of 2021,
Bristol Myers said.
(Reporting by Amruta Khandekar; Editing by
Shinjini Ganguli)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
